Hyfinity Investments

Jianda Biopharmaceuticals is a clinical-stage vaccine research and development company that develops innovative vaccines and new adjuvants.

ZD Medical develops innovative medical imaging technology, specifically phase variance optical coherence tomography, which enables the simultaneous detection of macular degeneration and retinal microvascular proliferation caused by diabetes. This non-invasive technology is designed for early detection of diabetic retinopathy, assisting healthcare professionals in identifying internal symptoms in patients. The company brings together a team of scientific and technological experts from various backgrounds to advance the development and manufacture of high-quality medical devices. ZD Medical is committed to providing practical solutions for medical diagnosis and clinical treatment, ultimately aiming to enhance healthcare outcomes and benefit public health.

Delova Biotech is focused on developing non-opioid analgesics aimed at pain treatment. The company leverages its extensive research and development experience, along with advanced preparation technology platforms, to enhance existing medications and create improved new analgesics in both China and the United States. Delova Biotech employs innovative technologies, including long-acting injection methods, transdermal formulations, nano-delivery systems, prodrug modifications, and techniques to improve the solubility of insoluble drugs. Through these efforts, the company strives to provide patients with higher quality medications that can significantly enhance their quality of life.

DPM Digital Precision Medicine specializes in the development of advanced medical equipment and innovative technology, particularly in the field of intraoperative molecular imaging. The company focuses on creating high-sensitivity and high-definition imaging solutions that enhance surgical navigation during procedures. By prioritizing research and development, DPM Digital Precision Medicine aims to deliver easy-to-operate imaging products that improve the precision and effectiveness of surgical interventions, catering to the needs of medical professionals.

Nuoyimeier is a developer of implantable consumables.

Immunowake is a biotechnology company dedicated to developing innovative therapies for patients who do not respond to current immunotherapies. The company aims to enhance the body's immune response against cancer by developing a universal cancer vaccine that generates safer and more effective bi-specific antibodies. By focusing on activating antigen-specific T-cells, Immunowake seeks to "wake up" the immune system, allowing it to identify and eliminate cancer cells more effectively. This approach not only strives to improve the efficacy of cancer treatments but also aims to reduce the associated toxicity for patients, ultimately enhancing their overall treatment experience.

InxMed is a clinical-stage biotechnology company dedicated to developing innovative cancer therapeutics aimed at improving treatment outcomes for patients. The company focuses on creating "Best-in-Disease Combination" medicines, which are designed to target various forms of cancer, including pancreatic, ovarian, and gastric cancers. InxMed's approach is grounded in a thorough understanding of disease biology and pharmacology, allowing for the development of novel treatment options. The company is committed to establishing a robust translational platform that combines advanced expertise with efficient execution capabilities to enhance the effectiveness of cancer therapies available to healthcare professionals and their patients.

Founded in 2020, Cargene Biopharma is a preclinical-stage biopharmaceutical company developing innovative oligonucleotide therapeutics for liver fibrosis and ophthalmic disorders, with operations in Singapore, USA and China. Cargene uses proprietary platforms backed by novel biology and chemistry insights, Cargene aims to improve quality of life for millions of patients worldwide through creating highly specific, stable and potent nucleic acid-based medicines for the treatment of a broad range of diseases.

Carcell Biopharma is a pre-clinical biotechnology company focused on the development of innovative cell and gene therapy products. The company specializes in engineered red blood cells aimed at immune regulation and employs non-viral vector gene delivery systems based on lipid nanoparticles. By utilizing a unique cross-border business model, Carcell Biopharma is dedicated to accelerating the discovery and development of next-generation therapies, positioning itself at the forefront of biopharmaceutical advancements.

Oculis is a global biopharmaceutical company focused on advancing eye care and preserving vision through innovative drug delivery solutions. The company's unique platform enables effective drug absorption in both the anterior and posterior segments of the eye, allowing for the treatment of conditions such as diabetic macular edema (DME) with a simple topical application, thus eliminating the need for invasive procedures. Oculis is developing several therapeutic candidates, including OCS-01, a topical treatment for DME; OCS-02, aimed at addressing dry eye disease; and OCS-05, which targets acute optic neuritis and other neuro-ophthalmic disorders. This novel approach not only facilitates treatment for posterior eye diseases but also reduces the required frequency of applications for anterior conditions compared to traditional eye drops.

Elpiscience Biopharmaceuticals Co., Ltd. is a clinical-stage immunology company based in Pudong, China, with an additional office in Suzhou. The company specializes in developing next-generation immunotherapies for cancer treatment, focusing on a diverse pipeline of innovative molecules that target various areas within immuno-oncology. Founded by experienced leaders and scientists in the biopharmaceutical industry, Elpiscience aims to advance at least one new therapeutic candidate into clinical trials each year, striving to enhance treatment options for cancer patients globally.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

Hexaell Biotechnology Co., Ltd is a start-up specializing in stem cell technology and artificial organs, focusing on innovative solutions for severe liver diseases. The company has licensed advanced technologies for developing bio-artificial livers that aim to replace human liver function and treat liver failure. Hexaell's research is based on findings published in prominent scientific journals, and it has conducted pilot clinical studies involving six liver failure patients at leading hepatopathy centers in China. By employing cell differentiation and production techniques, Hexaell is committed to providing effective treatment options for those suffering from liver conditions.

ipharmacare specializes in providing medical and health administration services focused on rational drug use management. The company offers a comprehensive set of solutions designed to support and monitor drug usage in clinical settings, utilizing real-world prescription data to enhance decision-making for medical institutions. Their management system aligns with the PDCA (Plan-Do-Check-Act) cycle, ensuring continuous improvement in drug use practices. Through these services, ipharmacare aims to enable healthcare providers to make informed and effective prescription choices, ultimately improving patient outcomes. For further inquiries, contact information is available on their website.